Soleno Therapeutics (NASDAQ:SLNO – Get Free Report) and Qualigen Therapeutics (NASDAQ:QLGN – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
Institutional & Insider Ownership
97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and target prices for Soleno Therapeutics and Qualigen Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Soleno Therapeutics | 1 | 1 | 12 | 1 | 2.87 |
| Qualigen Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Valuation & Earnings
This table compares Soleno Therapeutics and Qualigen Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Soleno Therapeutics | $190.40 million | 8.63 | $20.89 million | $0.23 | 138.43 |
| Qualigen Therapeutics | N/A | N/A | -$6.26 million | ($7.50) | -0.18 |
Soleno Therapeutics has higher revenue and earnings than Qualigen Therapeutics. Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Soleno Therapeutics and Qualigen Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Soleno Therapeutics | N/A | 5.90% | 4.61% |
| Qualigen Therapeutics | N/A | N/A | -202.16% |
Risk and Volatility
Soleno Therapeutics has a beta of -3.16, meaning that its stock price is 416% less volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500.
Summary
Soleno Therapeutics beats Qualigen Therapeutics on 12 of the 13 factors compared between the two stocks.
About Soleno Therapeutics
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
About Qualigen Therapeutics
Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
